Menkes disease and other ATP7A-related disorders
May. 14, 2024
MedLink®, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Nearly 3,000 illustrations, including video clips of neurologic disorders.
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
Full spectrum of neurology in 1,200 comprehensive articles.
Listen to MedLink on the go with Audio versions of each article.
In mammalian cells, ceramide is biosynthesized de novo or generated by catabolism of complex sphingolipids. In the de novo synthesis pathway (purple block arrow), a four-enzyme sequence culminates in the formation of ceramide from the amino acid serine and palmitoyl-CoA. This pathway is located in the endoplasmic reticulum. Sphingomyelin can be hydrolyzed to ceramide in the sphingomelin hydrolysis pathway (orange block arrow), which involves only one enzyme step. Alternatively, ceramide can be produced in the salvage pathway (green block arrows), through the acylation of sphingolipid by the ceramide synthase family of enzymes. The red blocks represent cartoons of the possible structures of the molecules. The acyl-chain length of ceramide can vary greatly. (Source: Abed Rabbo M, Khodour Y, Kaguni LS, Stiban J. Sphingolipid lysosomal storage diseases: from bench to bedside. Lipids Health Dis 2021;20[1]:44. Creative Commons Attribution 4.0 International License, http://creativecommons.org/licenses/by/4.0.)